Inactive Instrument
Sector ValiRx Plc London S.E.
Stocks
GB00B23N9136
Biotechnology & Medical Research
|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 08-10 | ValiRx subsidiary Cytolytix nears "significant" European patent win | AN |
| 08-10 | ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1.59% | -3.35% | +24.43% | +54.92% | +73.65% | +52.37% | +93.70% | +21.13% | - | 69.54B | |
| -1.34% | -0.75% | +15.42% | +25.10% | +24.89% | +48.21% | +91.86% | +210.83% | +6,204.23% | 64.97B | |
| +0.30% | -0.69% | +28.62% | +51.92% | +61.10% | +52.56% | +10.23% | -56.34% | - | 26.51B | |
| -2.35% | -5.75% | +14.95% | +10.88% | -31.89% | -12.90% | +448.54% | +341.00% | +798.03% | 25.89B | |
| -8.37% | -12.43% | +9.82% | +6.38% | +7.22% | +2.08% | -16.71% | -71.53% | - | 25.64B | |
| -0.96% | +10.36% | +43.06% | +84.28% | +264.65% | +283.06% | +436.50% | +1,783.06% | +1,035.46% | 20.22B | |
| -0.51% | +0.23% | +15.48% | +26.53% | +6.36% | +35.77% | -18.70% | -27.89% | +98.71% | 19.98B | |
| -1.91% | -4.37% | +3.40% | +11.36% | +31.18% | +13.28% | +535.19% | - | - | 15.69B | |
| -1.47% | +0.68% | -1.59% | +7.86% | +24.23% | +45.51% | +143.08% | +180.24% | +395.90% | 13.49B | |
| -1.83% | +3.29% | -2.40% | +7.34% | -8.34% | +21.90% | +197.38% | +543.08% | +5,153.54% | 12.33B | |
| -4.15% | -2.53% | -1.52% | +8.98% | +27.90% | +285.43% | +212.74% | +28.52% | +1,132.37% | 11.99B | |
| -5.78% | +5.65% | -0.31% | -19.26% | -15.62% | -38.76% | +164.86% | +160.88% | - | 11.2B | |
| -4.19% | +4.33% | +7.27% | -21.72% | -21.50% | -42.07% | +680.11% | +66.02% | +96.15% | 10.95B | |
| -7.46% | -6.18% | -8.03% | -6.08% | +13.46% | +104.05% | +103.13% | +116.62% | +491.39% | 10.02B | |
| -0.01% | +0.18% | +1.14% | +138.65% | +82.26% | +173.77% | +413.56% | +262.25% | - | 9B | |
| -2.16% | -4.45% | +12.94% | +16.41% | +29.68% | +94.33% | +15.47% | +124.61% | - | 8.9B | |
| -4.17% | +3.34% | +17.86% | +7.05% | +306.57% | +244.02% | +393.87% | -28.89% | - | 8.53B | |
| +1.58% | +6.21% | +1.27% | +1.39% | +16.39% | -14.62% | +113.50% | -15.69% | - | 8.51B | |
| -3.48% | -15.15% | -7.67% | +22.94% | +175.82% | +447.97% | +569.21% | -50.89% | -38.11% | 7.97B | |
| Average | -2.62% | -1.19% | +9.16% | +22.89% | +56.21% | +94.52% | +241.45% | +199.28% | +1,536.77% | 20.07B | |
| Weighted average by Cap. | -2.29% | -1.16% | +14.38% | +29.17% | +50.16% | +70.59% | +185.53% | +196.94% | +2,703.48% |
- Stock Market
- Stocks
- VAL Stock
- Stock
- Sector ValiRx Plc
Select your edition
All financial news and data tailored to specific country editions
